☆ 4.6 Article

Anticoagulant Treatment Regimens in Patients with Covid-19: A Meta-Analysis

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Related references

Note: Only part of the references are listed.

Review Cardiac & Cardiovascular Systems

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Luis Ortega-Paz et al.

Summary: This study presents evidence from randomized controlled trials comparing different prophylactic anticoagulation regimens among hospitalized patients with COVID-19. The findings suggest that standard-dose prophylactic anticoagulation is more suitable than escalated-dose regimen, as it does not reduce all-cause death but increases the risk of major bleeding.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2022)

Add to Collection

Article Medicine, General & Internal

Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19

Hanny Al-Samkari et al.

Summary: Among 3239 critically ill adults with COVID-19, 6.3% developed VTE and 2.8% experienced major bleeding. Early therapeutic anticoagulation did not impact survival in this cohort study.

ANNALS OF INTERNAL MEDICINE (2021)

Add to Collection

Article Immunology

Complement activation and endothelial perturbation parallel COVID-19 severity and activity

Massimo Cugno et al.

Summary: The study found that complement activation is enhanced during the progression of COVID-19 and dampened during remission, indicating its role in the pathophysiology of the disease. The association between complement activation and the biomarkers of endothelial damage suggests that complement may contribute to tissue injury and could be the target of specific therapy.

JOURNAL OF AUTOIMMUNITY (2021)

Add to Collection

Article Hematology

Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: the Multicenter Italian CORIST Study *

Augusto Di Castelnuovo et al.

Summary: This study evaluated the impact of heparin administration on survival in a large cohort of Italian COVID-19 patients and found that in-hospital heparin treatment was associated with a lower mortality rate, especially in severely ill patients and those with strong coagulation activation. Further results from randomized clinical trials are needed to provide clear recommendations.

THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis

Georg Gelbenegger et al.

Summary: The study indicates that short-term DAPT followed by ticagrelor monotherapy is associated with a more favorable outcome compared to standard DAPT, resulting in reduced all-cause mortality, net adverse clinical events, and major bleeding risk.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Critical Care Medicine

d-dimer and Death in Critically Ill Patients With Coronavirus Disease 2019

Samuel A. P. Short et al.

Summary: In critically ill patients with severe coronavirus disease 2019, higher levels of d-dimer were independently associated with a greater risk of death, even after multivariable adjustment. Therapeutic anticoagulation did not significantly affect this relationship.

CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial

Michelle Sholzberg et al.

Summary: This study aimed to evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards. The results of the study may help guide the treatment options for similar patients in the future.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19 The HEP-COVID Randomized Clinical Trial

Alex C. Spyropoulos et al.

Summary: Therapeutic-dose low-molecular-weight heparin reduces major thromboembolism and death in high-risk inpatients with COVID-19, with no significant effect observed in critically ill patients.

JAMA INTERNAL MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical Trial

Parham Sadeghipour et al.

Summary: This study compared the effect of intermediate-dose and standard prophylactic anticoagulation on a composite outcome among COVID-19 patients admitted to the ICU. The results showed no significant difference between the two groups in terms of thrombotic events, ECMO therapy, or mortality within 30 days. The study does not recommend routine use of intermediate-dose prophylactic anticoagulation in unselected ICU patients with COVID-19.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Critical Care Medicine

Inhaled budesonide for early treatment of COVID-19

Markus Zeitlinger et al.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Review Immunology

Associations of D-Dimer on Admission and Clinical Features of COVID-19 Patients: A Systematic Review, Meta-Analysis, and Meta-Regression

Runzhen Zhao et al.

Summary: The study revealed the association of plasma D-dimer with various clinical variables in COVID-19 patients through meta-analysis and meta-regression, supporting D-dimer as an independent predictor for mortality and complications. It also identified 22 variables independently correlated with D-dimer level, including respiratory rate and blood test parameters.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Hematology

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial

Usha S. Perepu et al.

Summary: In hospitalized adults with severe COVID-19, standard prophylactic dose and intermediate dose enoxaparin did not significantly differ in preventing death or thrombosis at 30 days. The occurrence of arterial or venous thrombosis was slightly higher than the rate of major bleeding.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Anticoagulation in COVID-19: reaction to the ACTION trial

Jeffrey S Berger et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Renato D. Lopes et al.

Summary: In hospitalized COVID-19 patients with elevated D-dimer concentration, in-hospital therapeutic anticoagulation with rivaroxaban or enoxaparin followed by rivaroxaban to day 30 did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. Therapeutic-dose rivaroxaban and other direct oral anticoagulants should be avoided in these patients without an evidence-based indication for oral anticoagulation.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Patrick R. Lawler et al.

Summary: This study showed that therapeutic-dose anticoagulation with heparin in non-critically ill patients with Covid-19 increased the likelihood of survival to hospital discharge and reduced the need for cardiovascular or respiratory organ support compared to usual-care thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Surviving Covid-19 with Heparin?

Hugo ten Cate

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Ewan C. Goligher et al.

Summary: In critically ill patients with Covid-19, initial therapeutic-dose anticoagulation did not result in improved survival rates or fewer days requiring cardiovascular or respiratory organ support compared to usual-care pharmacologic thromboprophylaxis.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Dawei Wang et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19

Ishan Paranjpe et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Article Hematology

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

Mauro Panigada et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Ning Tang et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Medicine, General & Internal

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Maximilian Ackermann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Hanny Al-Samkari et al.

BLOOD (2020)

Add to Collection

Letter Medicine, General & Internal

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Seda Bilaloglu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

Thomas Mandel Clausen et al.

CELL (2020)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Severe COVID-19 Is a Microvascular Disease

Charles J. Lowenstein et al.

CIRCULATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19

Girish N. Nadkarni et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Article Hematology

Routine haematological parameters in COVID-19 prognosis

David Pereyra et al.

Lancet Haematology (2020)

Add to Collection

Review Medicine, General & Internal

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

Baranca Buijsers et al.

EBIOMEDICINE (2020)

Add to Collection

Article Hematology

Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin

Courtney J. Mycroft-West et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

Anticoagulation and bleeding risk in patients with COVID-19

Nancy Musoke et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Article Hematology

Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)

Anna Cristina Bertoldi Lemos et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors

Zofia Wicik et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Hematology

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

S. Kaatz et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)

Add to Collection

Article Health Care Sciences & Services

Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness

Catalin Tufanaru et al.

INTERNATIONAL JOURNAL OF EVIDENCE-BASED HEALTHCARE (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium

Roxana Mehran et al.

CIRCULATION (2011)

Add to Collection

Article Mathematical & Computational Biology

A basic introduction to fixed-effect and random-effects models for meta-analysis

Michael Borenstein et al.

RESEARCH SYNTHESIS METHODS (2010)

Add to Collection

Article Medicine, General & Internal

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

Dagmar Kubitza et al.

CURRENT MEDICAL RESEARCH AND OPINION (2008)

Add to Collection

Article Mathematical & Computational Biology

Quantifying heterogeneity in a meta-analysis

JPT Higgins et al.

STATISTICS IN MEDICINE (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.